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Antimicrobial resistance in common pathogenic
bacteria is a globally important healthcare prob-
lem that complicates therapeutic decision-making
and impairs clinical outcomes in treated patients,
thereby risking treatment failure and increased
costs of care. Strategies to address antibiotic
resistance include improved surveillance of resist-
ance, public and professional education to foster
prudent antibiotic use, the implementation of
infection control measures, and the development
of new antibiotics and vaccines. National and
international authorities agree that rapid, con-
venient tests for bacterial infections, and for
certain resistant bacteria, are also needed to
improve antibiotic use and control antibiotic
resistance [1–5].
Indeed, the lack of point-of-care diagnostic
tools remains a key hindrance to the improve-
ment of prudent antibiotic prescribing. Cur-
rently, diagnostic tests that inﬂuence initial
management are rarely available in community
practice, and may take 48 h to deliver results
even in hospital. This means that most infections
cannot be accurately diagnosed at the time they
present to the clinician. This inevitably leads to
over-prescribing of antibiotics, often for virus
infections, at a time when antibiotic resistance is
increasing. It also means that patients may
receive an antibiotic unnecessarily and possibly
suffer an adverse drug reaction. While certain
categories of patient are known to be at
increased risk of infection by antibiotic-resistant
bacteria (e.g., children attending day care cen-
tres, recent recipients of antibiotic therapy,
nursing home residents), these categories are
too broad to signiﬁcantly improve antibiotic
usage.
In principle, therefore, rapid, convenient tests
applied at the point of prescribing have the
potential to:
• support the clinical diagnosis of infection;
• conﬁrm the nature of infection, thereby distin-
guishing between antibiotic-responsive and
antibiotic-non-responsive infections;
• support the appropriate selection of antibiotics,
thereby reducing adverse reactions, the selec-
tion pressure for resistance and the costs of
prescribing.
Accordingly, the topic of the 2005 Colloquium
of the International Forum on Antibiotic Resist-
ance (IFAR) was ‘Controlling antibiotic resistance
by rapid identiﬁcation of susceptible target infec-
tions and pathogen recognition’. Afﬁliated with
both the European Society of Clinical Microbio-
logy and Infectious Diseases (ESCMID; http://
www.escmid.org) and the International Society
for Infectious Diseases (ISID; http://www.
isid.org), the IFAR published its Global White
Paper on Bacterial Resistance in Community-
Acquired Respiratory Tract Infections in 2002
[4–9]. Since then, the IFAR has run a series of
annual colloquia on topics such as the role of
education, novel research models and regulatory
approaches in controlling antibiotic resistance
[10,11].
The 2005 IFAR Colloquium focused on the
current status and clinical application of rapid
diagnostic approaches to common bacterial infec-
tions, and how these might help to improve
antibiotic prescribing in both the hospital and
community settings. The meeting was divided
into two sections:
• Distinguishing antibiotic-requiring from antibi-
otic-non-requiring infections
This session covered the beneﬁts and limitations
of the latest tests that doctors can use to identify
patients with pharyngitis caused by bacteria (i.e.,
group A b-haemolytic streptococci) or viruses [12].
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Other sessions focused on the use of markers of
acute inﬂammation (especially procalcitonin) in
managing lower respiratory tract infections [13]
and approaches to the targeted management of
ventilator-associated pneumonia [14].
• Improving prescribing precision through rapid
identiﬁcation of speciﬁc target organisms
This session focused on the state-of-the-art
methods available to identify three organisms
associated with substantial levels of morbidity
and mortality, together with high rates of antimi-
crobial resistance, i.e., methicillin-resistant Sta-
phylococcus aureus [15], Streptococcus pneumoniae
[16] and Mycobacterium tuberculosis [17].
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